FDA Recall of Cipla's Cinacalcet Hydrochloride Tablets
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Cipla USA, Inc. is voluntarily recalling 113,336 bottles of Cinacalcet Hydrochloride Tablets due to CGMP deviations and presence of N-Nitroso Cinacalcet above acceptable limits.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on May 3, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action, a single localized FDA recall is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.
For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (recall, product-safety, cpsc, Drugs) map to related alerts in the same area of risk - browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.
What Happened
Cipla USA, Inc. is recalling certain lots of Cinacalcet Hydrochloride Tablets due to CGMP deviations and the presence of N-Nitroso Cinacalcet above the acceptable daily intake limit.
Which Products Are Affected
The affected product is Cinacalcet Hydrochloride Tablets, 30 mg, 30 tablets per bottle, manufactured by Cipla Ltd. for Cipla USA, Inc., with NDC: 69097-410-02. The recall includes lots: 4PB0526, 4PB0527, 4PB0528 with expiration September 2026, and 5PB0173 with expiration January 2027. A total of 113,336 bottles distributed nationwide in the USA are involved, under recall number D-0449-2026.
What You Should Do
Consumers should check if they have the affected lots and contact Cipla USA, Inc. as the recall was initiated via letter for further instructions on returns or refunds.
Why This Matters
This recall highlights potential risks from pharmaceutical manufacturing issues, affecting a large number of distributed bottles and underscoring the need for adherence to safety standards in drug production.
Source
Information from the FDA recall database, specifically recall event ID 98670.
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Frequently Asked Questions
Common questions about this FDA recall.